Drug Trial Radar · NCT07114055
Effect of Ebastine in Patients With Diarrhea Predominant Irritable Bowel Syndrome
Last checked: Nov 20, 2026Latest source record: Aug 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Aug 15, 2025
Primary completion
Jul 2026
Study completion Jul 2026
Sponsor
- Lead sponsor
- Md. Hazrat AliAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to assess and compare the effect of ebastine and placebo in improving symptoms in patients with diarrhea predominant IBS. It will also assess about the safety of drugs ebastine and placebo by recording the patient reported adverse events. The main questions it aim to answer are: Does drug ebastine and placebo has any effect on patients with IBS-D? What medical problems do participants have when taking drug ebastine and placebo? Researcher will compare effect of drug ebastine and placebo . Participant will: Take drug ebastine 20 mg at night and placebo once daily at night every day for 8 weeks along with lifestyle modifications. After that all two groups will visit the hospital 4 weekly, and their symptoms will be assessed by IBS symptom severity score (IBS-SSS) at baseline, week 4 and week 8. Additionally, patient reported adverse events will be documented.
Conditions
- Irritable Bowel Syndrome - Diarrhoea
Interventions
ebastineDrug
Tab. Ebastine 20mg once daily at night
PlaceboDrug
Tab. Placebo once daily at night
Primary outcomes
What the sponsor says the trial is designed to measure.
- 1. Improvement of diarrhea predominant IBS symptomsTime frame: [At baseline before randomization and then at week 4, and 8 ]
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Dhaka Medical College
Dhaka, Bangladesh · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.